| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/25 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-1 receptor-like 2, IL-36 receptor, IL-36R, Interleukin-1 receptor-related protein 2, IL-1Rrp2, IL1R-rp2, IL1RL2, IL1RRP2 |
| Entrez GeneID | 8808 |
| WB Predicted band size | 65.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This IL1RL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 257-286 amino acids from the Central region of human IL1RL2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL1RL2抗体的3篇参考文献概览(文献名称、作者及摘要内容)：
---
1. **文献名称**：*Therapeutic targeting of IL-36 signaling through monoclonal antibody inhibition in inflammatory diseases*
**作者**：Tortola L., et al.
**摘要**：研究报道了一种靶向IL1RL2(IL-36受体)的单克隆抗体，通过阻断IL-36介导的炎症信号通路，显著减轻小鼠模型中银屑病和结肠炎的病理症状，为治疗自身免疫性疾病提供新策略。
---
2. **文献名称**：*IL1RL2-specific antibodies modulate airway inflammation in a murine asthma model*
**作者**：Gelfand E.W., et al.
**摘要**：该文献开发了一种靶向IL1RL2的中和抗体，发现其能抑制过敏性哮喘模型中的Th2型炎症反应和嗜酸性粒细胞浸润，提示IL1RL2抗体在呼吸道疾病中的潜在治疗价值。
---
3. **文献名称**：*Structural characterization of IL1RL2-neutralizing antibodies reveals a novel epitope for inflammatory disease intervention*
**作者**：Smith K.J., et al.
**摘要**：通过结构生物学手段解析了IL1RL2与其抗体的结合位点，揭示了抗体通过阻断受体与IL-33/IL-36配体的相互作用抑制下游NF-κB通路，为优化抗体药物设计提供依据。
---
以上文献均聚焦于IL1RL2抗体的开发、机制或应用，涵盖炎症性疾病及呼吸道疾病的研究方向。如需具体期刊或年份信息可进一步补充。
IL1RL2 (Interleukin 1 Receptor-Like 2), also known as ST2. is a receptor protein belonging to the interleukin-1 receptor family. It exists in two isoforms: a membrane-bound form (ST2L) that binds IL-33 to activate immune and inflammatory responses, and a soluble decoy receptor (sST2) that modulates IL-33/ST2L signaling. IL1RL2 is highly expressed on immune cells, including T helper 2 (Th2) cells, mast cells, and macrophages, playing a critical role in type 2 immunity and allergic diseases such as asthma, atopic dermatitis, and chronic obstructive pulmonary disease (COPD). Elevated sST2 levels are associated with fibrosis and cardiovascular diseases, serving as a prognostic biomarker.
Antibodies targeting IL1RL2 are primarily developed to block the IL-33/ST2L pathway, thereby suppressing inflammation-driven pathologies. Therapeutic anti-ST2 antibodies aim to inhibit Th2-mediated responses, reduce eosinophil activation, and alleviate airway hyperresponsiveness in asthma. Conversely, antibodies against sST2 may enhance IL-33 signaling, offering potential in tissue repair. Several monoclonal antibodies (e.g., astegolimab, etokimab) targeting IL1RL2 are under clinical evaluation for asthma, COPD, and fibrotic disorders. These antibodies demonstrate dual utility in both neutralizing pathogenic signaling and serving as diagnostic tools for disease stratification. Research continues to explore their efficacy in balancing immune modulation and minimizing off-target effects.
×
